Abstract
Background:
Constipation is a concern among patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 3 and 4.
Objectives:
To assess naldemedine's efficacy and safety in cancer patients on opioids with poor PS.
Design:
Multicenter, retrospective study.
Setting/Subjects:
Japanese cancer patients with ECOG performance status 3 or 4 who received naldemedine.
Measurements:
Frequency of defecations before/after naldemedine use. Responders were patients whose defecation frequency increased to ≥3 times/week, from baseline ≥1 defecations/week over seven days after naldemedine administration.
Results:
Seventy-one patients were analyzed; 66.1% were responders (95% confidence interval: 54.5%–76.1%). Defecation frequency increased significantly after naldemedine in the overall population (6 vs. 2, p < 0.0001) and among those who defecated <3 times/week before naldemedine (4.5 vs. 1, p < 0.0001). Diarrhea (38.0%) of all grades was the most common adverse event; 23 (85.2%) events were classified as Grade 1 or 2.
Conclusion:
Naldemedine is effective and safe among cancer patients with poor PS.
Get full access to this article
View all access options for this article.
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
